The Novo Nordisk partnership provides validation for enobosarm + GLP-1 combo and removes drug supply cost for the Phase 2b trial, but the agreement is non-binding on future commercialization with a convenience termination clause. Monitor enrollment and topline data from the PLATEAU study as the next catalyst; near-term stock movement likely driven by news flow rather than fundamental changes.
Price Chart
Executive Summary
Veru Inc. entered a clinical supply agreement with Novo Nordisk under which Novo Nordisk will supply Wegovy (semaglutide) at no cost for Veru's Phase 2b PLATEAU study combining enobosarm with a GLP-1 RA in older adults with obesity. The agreement validates the combination approach and gives Novo Nordisk a right of first negotiation on enobosarm IP combination with Novo Nordisk GLP-1 products. No financial terms were disclosed, and the agreement can be terminated by Novo Nordisk on 60 days' notice.
Key Facts
- Veru entered a clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU study of enobosarm + Wegovy (semaglutide) in older adults with obesity.
- Novo Nordisk will supply Wegovy at no charge; Veru retains full global development/commercialization rights to enobosarm.
- Novo Nordisk received a right of first negotiation if Veru intends to develop/commercialize/license enobosarm combined with any Novo Nordisk GLP-1 product.
- Novo Nordisk may terminate the agreement for convenience upon 60 days' prior notice.
- Veru is solely responsible for conducting and sponsoring the Phase 2b study.
- No upfront payment, milestone, or royalty terms were disclosed.
Financial Impact
No revenue, cost savings, or financial terms disclosed. Study drug supply at no charge removes a cost for Veru, but all development costs remain with Veru. Upside from potential partnership or licensing outcome contingent on Phase 2b data.
Risk Factors
- Novo Nordisk can terminate for convenience on 60 days' notice, limiting deal certainty.
- No upfront or milestone payments disclosed — the agreement is purely supply-based with an ROFR.
- Phase 2b study may fail to meet endpoints, rendering the agreement moot.
- Veru retains all development costs; cash burn risk remains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019478 |
| Document: 0001437749-26-019478-index-headers.html | 0001437749-26-019478 |
| Document: 0001437749-26-019478-index.html | 0001437749-26-019478 |
| Document: 0001437749-26-019478.txt | 0001437749-26-019478 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Aug 10, 2026 11w ago | Press Release | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Jul 2, 2026 16w ago | 8-K / 424B5 | $3.06 $2.83 | ▲ +7.52% | ▲ +8.39% | $2.28 (+25.49%) |
Jun 4, 2026 20w ago | 8-K | $4.23 $3.40 | ▼ −19.62% | ▼ −17.02% | $2.28 (−46.10%) |
May 13, 2026 23w ago | 8-K | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
May 13, 2026 23w ago | Press Release | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers